Production of large-sized microdystrophins in an AAV-based vector configuration
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
An adeno-associated viral (AAV) vector containing an expression construct, wherein: the expression construct comprises a nucleic acid sequence which encodes a microdystrophin (MD); and the nucleic acid sequence encoding the MD has a size of at least 4.1 kb.
Core Innovation
The invention relates to an adeno-associated viral (AAV) gene-therapy approach for dystrophic diseases, in which an AAV expression construct encodes a microdystrophin (MD). The approach uses oversized DNA packaging constraints by providing a nucleic acid encoding microdystrophin with at least a 4.1 kb size while keeping the overall expression construct size to less than 6 kb. The microdystrophin includes a partial or full-length C terminal domain of dystrophin.
A central aspect is a CT-extended microdystrophin design with expanded functional domains that include dystrophin C terminal motifs and CT exons, specifically exons 70 to 79, with partial boundaries at exons 70 to 75. The constructs also include a central rod domain with a deletion ΔR4-23, while maintaining a partial or full-length C terminal domain encoded by exons 70 to 75 or exons 70 to 79, respectively. The design is evaluated in view of insert size, ITR-flanked cassette size, and construct constraints.
The documented constructs are packaged in AAV, including serotype 8 and serotype 9, and the expression is directed by a muscle-specific promoter, including Spc5-12. Validation in mdx and mdx4cv mouse models and in a canine CXMD model reports microdystrophin expression at the sarcolemma, dystrophin-positive fiber percentages, reduced muscle pathology and weight changes, and functional improvements such as eccentric contraction resistance.
Claims Coverage
The partial independent-claim set defines an AAV vector where the key inventive characteristics are (i) an expression construct encoding a microdystrophin with a dystrophin C terminal domain, (ii) size constraints on the microdystrophin nucleic acid and the overall expression construct, and (iii) additional structural microdystrophin elements in the second independent claim, including a central rod deletion and exon-encoded C terminal boundaries. Two inventive features are present.
AAV vector with microdystrophin encoding nucleic acid size and overall construct size constraints
An adeno-associated viral (AAV) vector comprising an expression construct encoding a microdystrophin (MD), wherein the nucleic acid sequence encoding the MD has a size of at least 4.1 kb and the expression construct has a size of less than 6 kb, and wherein the MD contains a partial or full-length C terminal domain of dystrophin.
Microdystrophin with central rod deletion and exon-encoded C terminal domain boundaries
An adeno-associated viral (AAV) vector comprising an expression construct encoding a microdystrophin (MD), wherein the nucleic acid sequence encoding the MD has a size of at least 4.1 kb, the MD contains a partial or full length C terminal domain of dystrophin, and the MD comprises a central rod domain having a deletion ΔR4-23 in the central rod domain, wherein the partial or full-length C terminal domain is encoded by exons 70 to 75 or exons 70 to 79, respectively.
Across the independent claims, the protected subject matter centers on AAV vectors with expression constructs that encode a microdystrophin including a dystrophin C terminal domain under stated size constraints, and, in the second independent claim, a specific microdystrophin architecture defined by ΔR4-23 in the central rod domain together with exon-encoded C terminal domain boundaries.
Stated Advantages
Microdystrophin expression at the sarcolemma.
Increased dystrophin-positive fiber percentages.
Reduced muscle pathology and changes in muscle weight.
Functional improvement, including eccentric contraction resistance.
DAP complex co-localization.
Membrane integrity restoration.
Documented Applications
AAV gene-therapy approach for dystrophic diseases, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), with treatment of a subject suffering from a dystrophic disease by administering an AAV composition as claimed.
Evaluation in mdx mouse model and mdx4cv mouse model for dystrophic disease effects, including microdystrophin expression and functional outcomes.
Evaluation in canine CXMD as a dystrophic disease model, reporting microdystrophin expression at the sarcolemma, DAP complex co-localization, and membrane integrity restoration.
Interested in licensing this patent?